Q3 2025 Novocure Ltd Earnings Call Transcript
Key Points
- NovoCure Ltd (NVCR) reported net revenues of $167 million for Q3 2025, marking an 8% increase from the same quarter last year.
- The company's GBM business continues to grow, with active patients increasing between 5% and 12% year over year for nine consecutive quarters.
- NovoCure Ltd (NVCR) received a positive national coverage decision from the Spanish Ministry of Health, expanding its international footprint.
- The company is preparing for the launch of Optune Lua in Japan, where it anticipates strong physician adoption due to the high prevalence of lung cancer and familiarity with device-based therapies.
- NovoCure Ltd (NVCR) is on track to become a platform therapy company with four cancer indications expected in the market by the end of 2026.
- The launch of Optune Lua for non-small cell lung cancer is behind expectations, with only 100 patients on therapy by the end of Q3 2025.
- Gross margin decreased to 73% due to the global rollout of HFE arrays, ongoing launch costs in non-small cell lung cancer, and increased tariffs.
- The US GBM active patient count was flat compared to Q3 2024, indicating challenges in expanding patient adoption in academic centers.
- NovoCure Ltd (NVCR) reported a net loss of $37 million for the quarter, with a loss per share of $0.33.
- The company faces challenges in introducing device-based therapies to medical oncology communities that have limited experience with such modalities.
Good day and thank you for standing by. Welcome to the Novocure third-quarter 2025 earnings call. (Operator Instructions)
Please be advised, today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ingrid Goldberg. Please go ahead.
Good morning, and thank you for joining us to review Novocure's third-quarter 2025 performance. I am on the phone this morning with our Executive Chairman, Bill Doyle; CEO, Ashley Cordova; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A.
For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Reports.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
